← Back to Search

Behavioral Intervention

Acceptance and Commitment Therapy for Cancer-Related Psychological Symptoms

N/A
Waitlist Available
Led By Miryam Yusufov, PhD
Research Sponsored by Dana-Farber Cancer Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
No Placebo-Only Group

Summary

This trial is developing an intervention to help cancer patients cope with psychological symptoms such as thoughts, feelings, emotions, and memories. It will assess the feasibility and acceptability of Acceptance & Commitment Therapy (ACT) to reduce risk of substance use disorder.

Who is the study for?
This trial is for adults over 18 with any type of cancer, expected to live at least 6 more months, and who are on opioid therapy with a risk for substance use disorder. They should be able to do daily activities with little to no help and must understand English well enough for psychotherapy.
What is being tested?
The study tests Acceptance & Commitment Therapy (ACT) adapted for cancer patients at risk of substance misuse due to opioid pain treatment. It involves six sessions with a psychologist, questionnaires, and an interview after the study.
What are the potential side effects?
Since ACT is a form of talk therapy focusing on mental health, it doesn't have physical side effects like drugs but can bring up strong emotions or distress as patients work through their thoughts and feelings.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Feasibility and acceptability of the intervention, as reported on semi-structured exit interviews
Secondary study objectives
Feasibility and acceptability of the intervention, as reported on the client satisfaction questionnaire - 8 (CSQ-8)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: INTERVENTION FOR AVOIDANCE-RELATED OPIOID MISUSEExperimental Treatment1 Intervention
Participants will participate in a six-session behavioral intervention, delivered by a licensed clinical psychologist.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Acceptance and Commitment Therapy
2010
Completed Phase 1
~1490

Find a Location

Who is running the clinical trial?

Dana-Farber Cancer InstituteLead Sponsor
1,108 Previous Clinical Trials
357,224 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,924 Previous Clinical Trials
41,017,938 Total Patients Enrolled
Miryam Yusufov, PhDPrincipal InvestigatorDana-Farber Cancer Institute
~5 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top